What is a stock summary page? Click here for an overview.
Business Description
Mersana Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US59045L1061
Compare
Compare
Traded in other countries / regions
MRSN.USA0M4.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2017-06-28Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.71 | |||||
| Equity-to-Asset | -0.07 | |||||
| Debt-to-Equity | -3.01 | |||||
| Debt-to-EBITDA | -0.45 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -9.07 | |||||
| Beneish M-Score | -1.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 591 | |||||
| 3-Year EBITDA Growth Rate | 39.9 | |||||
| 3-Year EPS without NRI Growth Rate | 38.5 | |||||
| 3-Year FCF Growth Rate | 30.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -8.08 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -20.01 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.28 | |||||
| 9-Day RSI | 26.5 | |||||
| 14-Day RSI | 30.69 | |||||
| 3-1 Month Momentum % | -66.47 | |||||
| 6-1 Month Momentum % | -72.82 | |||||
| 12-1 Month Momentum % | -88.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.19 | |||||
| Quick Ratio | 2.19 | |||||
| Cash Ratio | 2.16 | |||||
| Days Sales Outstanding | 11.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.2 | |||||
| Shareholder Yield % | -5.28 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -181.09 | |||||
| Net Margin % | -170.86 | |||||
| FCF Margin % | -203.65 | |||||
| ROE % | -533.43 | |||||
| ROA % | -37.7 | |||||
| ROIC % | -149.47 | |||||
| 3-Year ROIIC % | 409.38 | |||||
| ROC (Joel Greenblatt) % | -707.82 | |||||
| ROCE % | -53.39 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.13 | |||||
| EV-to-EBIT | 0.85 | |||||
| EV-to-EBITDA | 0.87 | |||||
| EV-to-Revenue | -1.36 | |||||
| EV-to-Forward-Revenue | 45.18 | |||||
| EV-to-FCF | 0.67 | |||||
| Price-to-GF-Value | 0.12 | |||||
| Earnings Yield (Greenblatt) % | 117.65 | |||||
| FCF Yield % | -177.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MRSN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mersana Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 40.497 | ||
| EPS (TTM) ($) | -0.56 | ||
| Beta | 0.29 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 80.08 | ||
| 14-Day RSI | 30.69 | ||
| 14-Day ATR ($) | 0.052113 | ||
| 20-Day SMA ($) | 0.47253 | ||
| 12-1 Month Momentum % | -88.8 | ||
| 52-Week Range ($) | 0.368 - 4.71 | ||
| Shares Outstanding (Mil) | 124.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mersana Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mersana Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mersana Therapeutics Inc Frequently Asked Questions
What is Mersana Therapeutics Inc(MRSN)'s stock price today?
The current price of MRSN is $0.37. The 52 week high of MRSN is $4.71 and 52 week low is $0.37.
When is next earnings date of Mersana Therapeutics Inc(MRSN)?
The next earnings date of Mersana Therapeutics Inc(MRSN) is 2025-05-09 Est..
Does Mersana Therapeutics Inc(MRSN) pay dividends? If so, how much?
Mersana Therapeutics Inc(MRSN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers